Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a large real-world database of patients with metastatic breast cancer.

Patients with BRCA1/2 mutations were found to have significantly shorter rwPFS with T-DXd (7.8 versus 9.2 months, hazard ratio 1.40, P = 0.02), which is consistent with what was observed in the DESTINY-Breast04 trial, 34 and patients with PD-L1 CPS ≥10 appeared to have numerically longer rwPFS with T-DXd (12.6 versus 6.9 months, hazard ratio 0.70, P = 0.31), which is also consistent with a positive trend observed in patients with a higher level of tumor infiltrating lymphocytes in DESTINY-Breast04.

also in 11,005 other papers